BXMPY (Beximco Pharmaceuticals) Asset Turnover: 0.17 (As of Dec. 2024)


What is Beximco Pharmaceuticals Asset Turnover?

Beximco Pharmaceuticals BXMPY 97 Asset Turnover is 0.17 as of Dec. 2024. GuruFocus rates BXMPY with a GF Score™ of 97/100. The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Beximco Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $100.05 Mil. Beximco Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $588.50 Mil. Therefore, Beximco Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 was 0.17.

Asset Turnover is linked to ROE % through Du Pont Formula. Beximco Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2024 was 14.74%. It is also linked to ROA % through Du Pont Formula. Beximco Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2024 was 10.12%.


Beximco Pharmaceuticals  (OTCPK:BXMPY) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Beximco Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=59.536/403.8835
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(59.536 / 400.18)*(400.18 / 588.498)*(588.498/ 403.8835)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.88 %*0.68*1.4571
=ROA %*Equity Multiplier
=10.12 %*1.4571
=14.74 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Beximco Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=59.536/588.498
=(Net Income / Revenue)*(Revenue / Total Assets)
=(59.536 / 400.18)*(400.18 / 588.498)
=Net Margin %*Asset Turnover
=14.88 %*0.68
=10.12 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Beximco Pharmaceuticals Asset Turnover Related Terms


Beximco Pharmaceuticals Asset Turnover Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Asset Turnover Chart

Beximco Pharmaceuticals Annual Data
Trend Dec15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.58 0.59 0.58 0.64

Beximco Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.16 0.16 0.17 0.17

BXMPY vs ZTS, UTHR: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Asset Turnover falls into.



Beximco Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Beximco Pharmaceuticals's Asset Turnover for the fiscal year that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2024 )/( (Total Assets (A: Jun. 2023 )+Total Assets (A: Jun. 2024 ))/ count )
=361.082/( (562.523+564.046)/ 2 )
=361.082/563.2845
=0.64

Beximco Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=100.045/( (576.687+600.309)/ 2 )
=100.045/588.498
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.17 mean?
Beximco Pharmaceuticals (BXMPY) has a Asset Turnover of 0.17 as of Dec. 2024. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Asset Turnover too high?
Beximco Pharmaceuticals' current Asset Turnover is 0.17. Overall, Beximco Pharmaceuticals has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Asset Turnover compare to ZTS and UTHR?
Beximco Pharmaceuticals' Asset Turnover of 0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Asset Turnover is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Asset Turnover of 0.17. The current Asset Turnover is 0.17. Beximco Pharmaceuticals' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Asset Turnover is 0.17 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.